Post-Traumatic Stress Disorder Therapeutics Global Market Report 2023

Description

“Post-Traumatic Stress Disorder Therapeutics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on post-traumatic stress disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for post-traumatic stress disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The post-traumatic stress disorder therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Antidepressants; Anti-Anxiety; Antihypertensive; Monoamine Oxidase (MAOs); Antipsychotics Or Second Generation Antipsychotics (SGOs); Beta-Blockers; Other Classes

2) By Age Group: Pediartic; Geriatric; Adult

3) By End User: Mental Health Center; Hospitals; Outpaitent Clinics; Other End Users

Companies Mentioned: Novartis AG; Pfizer Inc.; Bionomics Ltd.; Apotex Inc.; GlaxoSmithKline PLC.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the post-traumatic stress disorder therapeutics market are Novartis AG, Pfizer Inc., Bionomics Ltd., Apotex Inc., GlaxoSmithKline PLC., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Pvt Ltd., Strategic Behavioral Health, Jazz Pharmaceuticals, Bionomics, Behavioral Health Network Inc., AstraZeneca PLC., Apotex Inc., Prometheon Pharma LLC., Ligand Pharmaceuticals Incorporated, Lycera Corp. and JSC Valenta Pharm.

The global post-traumatic stress disorder therapeutics market is expected to grow from $3.15 billion in 2022 to $3.42 billion in 2023 at a compound annual growth rate (CAGR) of 8.72%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The post-traumatic stress disorder therapeutics market is expected to reach $4.82 billion in 2027 at a CAGR of 8.96%.

The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Post-traumatic stress disorder therapeutics refers to therapeutics used to treat post-traumatic stress disorder (PTSD), a mental health condition triggered by either experiencing it or witnessing it. Post-traumatic stress disorder treatment helps to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition.

North America was the largest region in the post-traumatic stress disorder therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main drugs in post-traumatic stress disorder therapeutics include antidepressants, anti-anxiety, antihypertensive, monoamine oxidase (MAOS), antipsychotics or second-generation antipsychotics (SGOS), beta-blockers, others (benzodiazepines and others). Antidepressants refer to a class of drugs that are used to manage addictions and treat illnesses like major depressive disorder, anxiety disorders, and chronic pain. The age group receiving the therapeutics includes pediatric, geriatric, and adults, by various end users including mental health centers, hospitals, outpatient clinics, and others.

The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, according to the United States Department of Veterans Affairs, a US-based government department, Nearly 8 million Americans are suffering from PTSD condition in 2021. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market.

Strategic collaborations, funding, and investments have emerged as a key trend gaining popularity in the post-traumatic stress disorder therapeutics market. Major companies operating in the market are developing strategic collaborations and investing in the companies to strengthen their position in the market. For instance, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University, members of an interdisciplinary research team were given over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). The initiative is one of seven clinical studies under the Medical Research Future Fund (MRFF) unveiled this month by the Federal government to evaluate the use of potentially ground-breaking combination medicines to treat crippling mental diseases.

In October 2020, Jazz Pharmaceuticals Ireland Limited, an Ireland-based biopharmaceutical company acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program, including PF-04457845 for an undisclosed amount. Through this acquisition, Jazz will first concentrate on creating PF-04457845 in order to research its potential for treating post-traumatic stress disorder ("PTSD") and its symptoms. SpringWorks is a US-based clinical-stage biopharmaceutical company.

The countries covered in the post-traumatic stress disorder therapeutics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The post-traumatic stress disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed sulfuric acid market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This sulfuric acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r6435

1. Executive Summary

2. Post-Traumatic Stress Disorder Therapeutics Market Characteristics

3. Post-Traumatic Stress Disorder Therapeutics Market Trends And Strategies

4. Post-Traumatic Stress Disorder Therapeutics Market - Macro Economic Scenario

4.1. COVID-19 Impact On Post-Traumatic Stress Disorder Therapeutics Market
4.2. Ukraine-Russia War Impact On Post-Traumatic Stress Disorder Therapeutics Market
4.3. Impact Of High Inflation On Post-Traumatic Stress Disorder Therapeutics Market

5. Post-Traumatic Stress Disorder Therapeutics Market Size And Growth

5.1. Global Post-Traumatic Stress Disorder Therapeutics Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global Post-Traumatic Stress Disorder Therapeutics Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. Post-Traumatic Stress Disorder Therapeutics Market Segmentation

6.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Antidepressants
Anti-Anxiety
Antihypertensive
Monoamine Oxidase (MAOs)
Antipsychotics Or Second Generation Antipsychotics (SGOs)
Beta-Blockers
Other Classes
6.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Pediartic
Geriatric
Adult
6.3. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Mental Health Center
Hospitals
Outpaitent Clinics
Other End Users

7. Post-Traumatic Stress Disorder Therapeutics Market Regional And Country Analysis

7.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market

8.1. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Post-Traumatic Stress Disorder Therapeutics Market

9.1. China Post-Traumatic Stress Disorder Therapeutics Market Overview
9.2. China Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Post-Traumatic Stress Disorder Therapeutics Market

10.1. India Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Post-Traumatic Stress Disorder Therapeutics Market

11.1. Japan Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Post-Traumatic Stress Disorder Therapeutics Market

12.1. Australia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Post-Traumatic Stress Disorder Therapeutics Market

13.1. Indonesia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Post-Traumatic Stress Disorder Therapeutics Market

14.1. South Korea Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Post-Traumatic Stress Disorder Therapeutics Market

15.1. Western Europe Post-Traumatic Stress Disorder Therapeutics Market Overview
15.2. Western Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Post-Traumatic Stress Disorder Therapeutics Market

16.1. UK Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Post-Traumatic Stress Disorder Therapeutics Market

17.1. Germany Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Post-Traumatic Stress Disorder Therapeutics Market

18.1. France Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market

19.1. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market Overview
19.2. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Post-Traumatic Stress Disorder Therapeutics Market

20.1. Russia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Post-Traumatic Stress Disorder Therapeutics Market

21.1. North America Post-Traumatic Stress Disorder Therapeutics Market Overview
21.2. North America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Post-Traumatic Stress Disorder Therapeutics Market

22.1. USA Post-Traumatic Stress Disorder Therapeutics Market Overview
22.2. USA Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Post-Traumatic Stress Disorder Therapeutics Market

23.1. South America Post-Traumatic Stress Disorder Therapeutics Market Overview
23.2. South America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Post-Traumatic Stress Disorder Therapeutics Market

24.1. Brazil Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Post-Traumatic Stress Disorder Therapeutics Market

25.1. Middle East Post-Traumatic Stress Disorder Therapeutics Market Overview
25.2. Middle East Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Post-Traumatic Stress Disorder Therapeutics Market

26.1. Africa Post-Traumatic Stress Disorder Therapeutics Market Overview
26.2. Africa Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Post-Traumatic Stress Disorder Therapeutics Market Competitive Landscape And Company Profiles

27.1. Post-Traumatic Stress Disorder Therapeutics Market Competitive Landscape
27.2. Post-Traumatic Stress Disorder Therapeutics Market Company Profiles
- 27.2.1. Novartis AG
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. Pfizer Inc.
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Bionomics Ltd.
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Apotex Inc.
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. GlaxoSmithKline plc
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Post-Traumatic Stress Disorder Therapeutics Market

29. Post-Traumatic Stress Disorder Therapeutics Market Future Outlook and Potential Analysis

30. Appendix

30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. The Business Research Company
30.6. Copyright And Disclaimer